Enlivex Treasury Portfolio Update: New Listing of the RAIN Token on Kraken, the Second-Largest U.S. Cryptocurrency Exchange
Rhea-AI Summary
Enlivex (Nasdaq: ENLV) announced that its primary treasury asset, the RAIN token, was listed on Kraken effective February 9, 2026. The company says the listing expands token access and aims to enhance secondary market liquidity, price discovery, and accessibility for RAIN users and governance participants.
Kraken serves about 5.7 million users and reported over $2 trillion in 2025 trading volume, making it a major access point for institutional and retail digital-asset trading.
Positive
- Listing on Kraken expands RAIN access to ~5.7 million users
- 2025 Kraken trading volume exceeded $2 trillion, supporting liquidity
- Potential for improved price discovery and secondary market liquidity
Negative
- None.
News Market Reaction – ENLV
On the day this news was published, ENLV declined NaN%, reflecting a moderate negative market reaction.
Data tracked by StockTitan Argus on the day of publication.
Key Figures
Market Reality Check
Peers on Argus
ENLV is down about 0.86% while peer moves are mixed: AKTX, ICU, TENX show gains/losses and only ICU appears in momentum scanners with a -4.12% move and no news. With just one peer in momentum and no common headlines, ENLV’s action looks stock-specific rather than a broad biotech or healthcare rotation.
Previous Crypto Reports
| Date | Event | Sentiment | Move | Catalyst |
|---|---|---|---|---|
| Jan 26 | RAIN WhiteBIT listing | Positive | +8.3% | RAIN token listed on WhiteBIT to broaden access and liquidity. |
| Jan 07 | RAIN KuCoin listing | Positive | +0.4% | KuCoin listing positioned RAIN on a major global crypto venue. |
| Nov 20 | Bitcoin treasury plan | Positive | -5.2% | Board approved up to <b>$1 million</b> in Bitcoin as treasury reserve. |
Crypto/treasury updates have produced mixed but generally modest moves, with two positive reactions and one negative, averaging about 1.15% over the last three crypto-tag events.
Over recent months, Enlivex has steadily built a digital-asset-focused treasury strategy. Prior crypto-tag news included RAIN listings on KuCoin and WhiteBIT, which aimed to expand access and liquidity and saw 24-hour moves of 0.37% and 8.33%. Earlier, the company adopted a Bitcoin treasury reserve approach with a $1 million authorization, which coincided with a -5.24% reaction. Today’s Kraken listing continues this pivot toward crypto-centric treasury management.
Historical Comparison
In the past 12+ months, ENLV issued three crypto-related treasury updates, averaging a 1.15% move and spanning reactions from +8.33% to -5.24%. The Kraken RAIN listing fits this ongoing pattern of exchange-access and treasury-strategy announcements.
Crypto-tag history shows a progression from adopting a Bitcoin reserve, to concentrating the treasury in RAIN, and then adding major exchange listings like KuCoin, WhiteBIT, and now Kraken to deepen liquidity and access for the token.
Market Pulse Summary
This announcement extends Enlivex’s digital-asset treasury strategy by adding a Kraken listing for its primary RAIN token, potentially broadening access via a platform with 5.7 million users and over $2 trillion in 2025 volume. In context of prior KuCoin and WhiteBIT listings and earlier Bitcoin reserve plans, key factors to monitor include actual RAIN trading liquidity, treasury concentration in digital assets, and continued progress in the underlying Allocetra clinical program.
Key Terms
governance and utility token technical
decentralized predictions and options protocol technical
Arbitrum network technical
secondary market liquidity financial
derivatives markets financial
on-chain technical
AI-generated analysis. Not financial advice.
Additional exchange listing expected to increase token access and contribute to expanded secondary market liquidity for RAIN
Nes-Ziona, Israel, Feb. 10, 2026 (GLOBE NEWSWIRE) -- Enlivex Therapeutics Ltd. (Nasdaq: ENLV, “Enlivex” or “the Company”) today reported that its primary treasury asset, the RAIN token, has been listed on the Kraken cryptocurrency exchange effective February 9, 2026, further expanding access to the token across an additional digital asset trading platform.
Kraken is the second-largest U.S.-based cryptocurrency exchange, and was founded in 2011. The exchange serves 5.7 million users across numerous jurisdictions and supports a broad range of digital assets through spot and derivatives markets, and its 2025 total trading volume was more than
The Company believes that the listing of the Rain token on Kraken will contribute to increased liquidity, improved price discovery, and enhanced accessibility for participants in the RAIN ecosystem. RAIN serves as the governance and utility token of a fully decentralized predictions and options protocol built on the Arbitrum network. The protocol enables users globally to create, trade, and resolve markets tied to real-world events through a transparent and automated on-chain framework.
ABOUT ENLIVEX
Enlivex is a clinical stage macrophage reprogramming immunotherapy company currently focused on the late-stage clinical development of Allocetra™, a novel therapy designed to treat the joint disease osteoarthritis. Additionally, Enlivex is the first publicly-listed company to have developed a treasury strategy centered on RAIN, which currently serves as the primary treasury reserve asset of the Company. In adopting its treasury policy, Enlivex intends to provide investors with exposure to RAIN and to advocate for its role as digital capital.
With respect the Company’s clinical development focus, osteoarthritis is by far the most common form of arthritis, affecting more than 32.5 million Americans and more than 300 million individuals worldwide. About half of knees with ACL injuries develop osteoarthritis within 5 to 15 years. 78 million Americans are projected to have osteoarthritis by the year 2040. Symptomatic knee osteoarthritis is particularly prevalent and disabling, with
Forward-Looking Statements
This press release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. These forward-looking statements may be identified by words such as “expects,” “plans,” “projects,” “will,” “may,” “anticipates,” “believes,” “should,” “would,” “could,” “intends,” “estimates,” “suggests,” “target,” “has the potential to,” “goal,” and other words of similar meaning, including statements relating to the anticipated benefits of expanded exchange listings of the RAIN token; the expected impact of such listings on market access, trading activity, liquidity, and price discovery for RAIN; the role of exchange availability in supporting the Company’s digital asset treasury strategy; the relationship between digital asset liquidity and market participation; the potential impact of digital asset market dynamics on the liquidity and trading characteristics of the Company’s ordinary shares; macroeconomic, political, and regulatory conditions surrounding digital assets; the Company’s plans for value creation and strategic positioning; regulatory conditions; competitive position; technological and market trends; future financial condition and performance; expected clinical trial results; market opportunities for the results of current clinical studies and preclinical experiments; and the effectiveness of, and market opportunities for, ALLOCETRA™ programs. Each forward-looking statement contained in this press release is subject to risks and uncertainties that could cause actual results to differ materially from those expressed or implied by such statement. Applicable risks and uncertainties include, among others, the risk of failure to realize the anticipated benefits of expanded exchange listings; changes in business, market, financial, political, and regulatory conditions; risks relating to the Company’s operations and business, including the highly volatile nature of the price, trading volume, and liquidity of RAIN and other cryptocurrencies; risks associated with digital asset exchange listings, trading venues, custody, and market infrastructure; the risk that the price and liquidity of the Company’s ordinary shares may be correlated with the price or liquidity of the digital assets it holds; risks relating to increased competition in the industries in which the Company operates; risks relating to significant legal, commercial, regulatory, and technical uncertainty regarding digital assets generally; risks relating to the treatment of crypto assets for U.S. and foreign tax purposes; and those risks and uncertainties identified in the Company’s filings with the Securities and Exchange Commission. The forward-looking statements in this press release speak only as of the date of this document, and the Company undertakes no obligation to update or revise any of these statements, except as required by applicable law.
ENLIVEX CONTACT
Shachar Shlosberger, CFO
Enlivex Therapeutics, Ltd.
shachar@enlivex.com
INVESTOR RELATIONS CONTACT
KCSA Strategic Communications
Jack Perkins
Enlivex@KCSA.com